Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
0(0%)
Results Posted
100%(16 trials)

Phase Distribution

Ph phase_1
14
88%
Ph phase_2
2
13%

Phase Distribution

14

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
14(87.5%)
Phase 2Efficacy & side effects
2(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

16 of 16 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(16)

Detailed Status

Completed16

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 114 (87.5%)
Phase 22 (12.5%)

Trials by Status

completed16100%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_1

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

NCT06023095
completedphase_1

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

NCT05086445
completedphase_1

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

NCT05841238
completedphase_1

A Study of LY3502970 in Healthy Participants

NCT03929744
completedphase_1

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.

NCT05936138
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT06023095Phase 1

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

Completed
NCT05086445Phase 1

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

Completed
NCT05841238Phase 1

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Completed
NCT03929744Phase 1

A Study of LY3502970 in Healthy Participants

Completed
NCT05936138Phase 1

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.

Completed
NCT05051566Phase 1

A Multiple Dose Study of LY3502970 in Healthy Participants

Completed
NCT06085482Phase 1

A Phase I Study of LY3502970 in Healthy Participants

Completed
NCT05469126Phase 1

A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants

Completed
NCT05341089Phase 1

A Study of Two Different Formulations of LY3502970 in Healthy Participants

Completed
NCT05882032Phase 1

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

Completed
NCT05573230Phase 1

A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants

Completed
NCT04426474Phase 1

A Study of LY3502970 in Participants With Type 2 Diabetes

Completed
NCT05313802Phase 1

A Study of LY3502970 in Healthy Overweight and Obese Participants

Completed
NCT05110794Phase 1

A Multiple-Dose Study of LY3502970 in Healthy Participants

Completed
NCT05048719Phase 2

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

Completed
NCT05051579Phase 2

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16